Post by Kymera Therapeutics

Name: Today, we announced new preclinical lupus data for KT-579, our first-in-class, oral IRF5 degrader, a
Uploaded: 2026-06-08T11:02:59.949Z
Channel: Kymera Therapeutics
Description: Today, we announced new preclinical lupus data for KT-579, our first-in-class, oral IRF5 degrader, at the EULAR - European Alliance of Associations for Rheumatology and Federation of Clinical Immunolo

45,131 followers

Today, we announced new preclinical lupus data for KT-579, our first-in-class, oral IRF5 degrader, at the EULAR - European Alliance of Associations for Rheumatology and Federation of Clinical Immunology Societies (FOCIS) congresses. IRF5 is a historically undrugged target that unlocks key biological pathways implicated in complex autoimmune diseases. The data shared highlight KT-579’s compelling preclinical profile and its potential to offer a novel oral therapy. Learn more: https://bit.ly/43mDOWZ #RevolutionizingImmunology

Video Content